期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

P53 Ki67在三阴乳腺癌中的表达及意义 被引量：3

下载PDF
导出
摘要 乳腺癌是全球范围内女性最常见的恶性肿瘤，并且其发病率还在以每年2％的速度递增，且呈年轻化趋势。三阴乳腺癌是指雌激素受体（E R ）、孕激素受体（PR）及人表皮生长因子受体（Her-2）均为阴性的乳腺癌，约占乳腺癌的10％～17％。这一类乳腺癌具有高度侵袭性，患者复发率高，5年生存率低，对内分泌治疗不敏感。本研究利用免疫组织化学法对128例三阴乳腺癌及168例非三阴乳腺癌组织中 P53及Ki67的表达进行比较，现报告如下。
作者 刘志英 冬国友 王俊然
机构地区 河北省唐山市妇幼保健院乳腺外科 河北省唐山市妇幼保健院病理科
出处 《山西医药杂志》 CAS 2014年第6期632-633,共2页 Shanxi Medical Journal
关键词 三阴乳腺癌 人表皮生长因子受体 免疫组织化学法 年轻化趋势 雌激素受体 HER-2 孕激素受体 高度侵袭性
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Nielsen TO, Hsu FD, Jensen K, et al. Advantage and the in- cidence of the basalcarcinoma[J]. Clin Cancer Res, 2006, 10 (2) 5367-5374.
  • 2Dent R,Trudeau M,Pritchard KJ,et al. Triple negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13 (5) : 4429-4434.
  • 3Perou CM, Sorlic T, Eisen MB, et al. Molecular portraits of human breast cancer[J]. Nature, 2000,406(6797) :747-752.
  • 4Iwamb P,Crawford L. Charaeterization of the human p53 gene [J]. Molcell Bio1,1986,6(5) :1379-1385.
  • 5Bidard FC, Matthieu MC, Chollet P, et ai. p53 status and ef- ficacy of primary anthracyelines/alkylating agent-based regi- men according to breast cancer molecular classes[J]. Ann On- col,2008, 19(7) 1261-1265.
  • 6Menezes MV, Cestari AL, Almeida O, et al. Protein expres- sion of Cerb-2 and p53 in normal ducts,ductal carcinoma in situ and invasive carcinoma of the same breast[J]. Sao Paulo Med J, 2006,124(3) : 121-124.
  • 7Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen as- sociated with cell proliferation[J]. Int J Cancer, 1983,31 (1) . 13.
  • 8邓秀娟,吴海根.Ki67、PTEN在卵巢浆液性肿瘤中的表达及临床意义[J].实用癌症杂志,2011,26(4):365-367. 被引量：15
  • 9祝玉祥,章佳新,邵稳喜,何春兰,诸林海,符德元.ki67在三阴性乳腺癌组织中的表达及意义[J].中国现代普通外科进展,2010,13(9):679-680. 被引量：12

二级参考文献15

  • 1邵汇琳,沈丹华,薛卫成,李艺,虞有智.卵巢上皮性肿瘤的临床病理特征及其细胞周期素D1和p53蛋白表达的研究[J].中华妇产科杂志,2007,42(4):227-232. 被引量：10
  • 2Tan PH,Bay BH,Yip G,et al.Immunohistochemical detection of ki67in breast cancer correlates with transcriptional regulation of genes related to apoptasis and cell death[J].Mod Pathol,2005,18(3):374-381.
  • 3Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(2):5367-5374.
  • 4Siziopkou KP,Cobleigh M.The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies[J].Breast,2007,16(1):104-107.
  • 5Dent R,Trudeau M,Pritchard KJ,et al.Triple negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(5):4429-4434.
  • 6Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA,2001,98(6):10869-10874.
  • 7ivasy CA,Karaca G,Nanda R,et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J[.Mod Pathol,2006,19(2):264-271.
  • 8Rakha EA,EI-Sayed ME,Green AR,et al.Prognostic markers in triple negative breast cancer[J].Cancer,2006,109(1):25-32.
  • 9Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J].J Clin Oncol,2006,24(6):5652-:5657.
  • 10Bhataydekar JM,Patel DD,Shah NG,et al.Prognostic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stageⅢ breast cancer,a multivariate analysis[J].Ann Surg Oncol,2000,7(4):305-311.

共引文献24

同被引文献24

  • 1工斐,余之刚.乳腺癌预防和筛查新进展[J].临床普外科电子杂志,2013,1(1):57-61. 被引量：7
  • 2Pilati P, Nitti D, Mocellin S. Cancer resistance to type II topoisomerase inhibitors[ J ]. Curr M ed Chem,2012, 19 (23) : 3900 - 3906.
  • 3Harem C,EI- Masri M,Poliquin G, et al. A single- centre chart review exploring the adjusted association between breast cancer phenotype and prognosis [ J ]. Curr Oncol,2011,18(4) :191 -196.
  • 4Lara - Medina F, Parez - Sanchez V, et al. Triple - negative breast cancer in Hispanic patients:high prev- alence, poor prognosis, and association with menopaus- al status, body mass index, and parity [ J ]. Cancer, 2011,117(16) :3658 -3669.
  • 5Lee JA,Kim KI. Triple negative breast cancer in korea- distinct biology with different impact of prognostic fac- tors on survival [ J ]. Breast Cancer Treat, 2010, 123 (1) :177 -187.
  • 6Chae B J, Bae JS, Lee A. P53 as a specific prognostic factor in triple- negative breast cancer[ J]. Clin On- col,2009,39:217 - 224.
  • 7Reiki Nishimura,Nobuyuki Arima. Is triple negative a prognostic factor in breast cancer [ J ] Breast Cancer, 2008,15:303 - 308.
  • 8Tiwary R, Yu W, Sanders BG, Kline K, et al. ot - TEA cooperates with chemotherapeutic agents to induce ap- optosis of p53 mutant, triple - negative human breast cancer cells via activating p73 [ J ]. Breast Cancer, 2011,13 ( 1 ) :3721 - 3723.
  • 9Moriya T, Kanomata N, KozuKa Y, et al. Moleaular morphological approach to the pathological study of development and advancement of human breast cancer [J]. Med Morphol,2010,43(2) :67.
  • 10Chen J, Solomides C, Simpkins H, et al. Sensitization of mesothelioma cells to platinum - based chemother- apy by GSTπ knockdown [ J ]. Biochem - Biophys Commun,2014,447 ( 1 ) :77 - 82.

引证文献3

二级引证文献17

山西医药杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部